Cargando…
Immunogenic ferroptosis and where to find it?
Ferroptosis is a recently discovered form of regulated cell death that is morphologically, genetically, and biochemically distinct from apoptosis and necroptosis, and its potential use in anticancer therapy is emerging. The strong immunogenicity of (early) ferroptotic cancer cells broadens the curre...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671998/ https://www.ncbi.nlm.nih.gov/pubmed/34903554 http://dx.doi.org/10.1136/jitc-2021-003430 |
_version_ | 1784615267448389632 |
---|---|
author | Demuynck, Robin Efimova, Iuliia Naessens, Faye Krysko, Dmitri V |
author_facet | Demuynck, Robin Efimova, Iuliia Naessens, Faye Krysko, Dmitri V |
author_sort | Demuynck, Robin |
collection | PubMed |
description | Ferroptosis is a recently discovered form of regulated cell death that is morphologically, genetically, and biochemically distinct from apoptosis and necroptosis, and its potential use in anticancer therapy is emerging. The strong immunogenicity of (early) ferroptotic cancer cells broadens the current concept of immunogenic cell death and opens up new possibilities for cancer treatment. In particular, induction of immunogenic ferroptosis could be beneficial for patients with cancers resistant to apoptosis and necroptosis. However, ferroptotic cancer cells may be a rich source of oxidized lipids, which contribute to decreased phagocytosis and antigen cross-presentation by dendritic cells and thus may favor tumor evasion. This could explain the non-immunogenicity of late ferroptotic cells. Besides the presence of lactate in the tumor microenvironment, acidification and hypoxia are essential factors promoting ferroptosis resistance and affecting its immunogenicity. Here, we critically discuss the crucial mediators controlling the immunogenicity of ferroptosis that modulate the induction of antitumor immunity. We emphasize that it will be necessary to also identify the tolerogenic (ie, immunosuppressive) nature of ferroptosis, which can lead to tumor evasion. |
format | Online Article Text |
id | pubmed-8671998 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-86719982021-12-28 Immunogenic ferroptosis and where to find it? Demuynck, Robin Efimova, Iuliia Naessens, Faye Krysko, Dmitri V J Immunother Cancer Review Ferroptosis is a recently discovered form of regulated cell death that is morphologically, genetically, and biochemically distinct from apoptosis and necroptosis, and its potential use in anticancer therapy is emerging. The strong immunogenicity of (early) ferroptotic cancer cells broadens the current concept of immunogenic cell death and opens up new possibilities for cancer treatment. In particular, induction of immunogenic ferroptosis could be beneficial for patients with cancers resistant to apoptosis and necroptosis. However, ferroptotic cancer cells may be a rich source of oxidized lipids, which contribute to decreased phagocytosis and antigen cross-presentation by dendritic cells and thus may favor tumor evasion. This could explain the non-immunogenicity of late ferroptotic cells. Besides the presence of lactate in the tumor microenvironment, acidification and hypoxia are essential factors promoting ferroptosis resistance and affecting its immunogenicity. Here, we critically discuss the crucial mediators controlling the immunogenicity of ferroptosis that modulate the induction of antitumor immunity. We emphasize that it will be necessary to also identify the tolerogenic (ie, immunosuppressive) nature of ferroptosis, which can lead to tumor evasion. BMJ Publishing Group 2021-12-13 /pmc/articles/PMC8671998/ /pubmed/34903554 http://dx.doi.org/10.1136/jitc-2021-003430 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Demuynck, Robin Efimova, Iuliia Naessens, Faye Krysko, Dmitri V Immunogenic ferroptosis and where to find it? |
title | Immunogenic ferroptosis and where to find it? |
title_full | Immunogenic ferroptosis and where to find it? |
title_fullStr | Immunogenic ferroptosis and where to find it? |
title_full_unstemmed | Immunogenic ferroptosis and where to find it? |
title_short | Immunogenic ferroptosis and where to find it? |
title_sort | immunogenic ferroptosis and where to find it? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671998/ https://www.ncbi.nlm.nih.gov/pubmed/34903554 http://dx.doi.org/10.1136/jitc-2021-003430 |
work_keys_str_mv | AT demuynckrobin immunogenicferroptosisandwheretofindit AT efimovaiuliia immunogenicferroptosisandwheretofindit AT naessensfaye immunogenicferroptosisandwheretofindit AT kryskodmitriv immunogenicferroptosisandwheretofindit |